Teva Loses 180-Day Exclusivity For Generic Actonel As FDA Stands Firm On Review Delays
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan’s product launches as FDA tells Teva that the agency’s delay in granting tentative ANDA approval does not prevent forfeiture of exclusivity.